This observational study examined the safety of combining Helixor® Viscum album L. (a mistletoe extract) with targeted therapy in breast and gynecological cancer patients. The study included 242 patients, with 160 receiving only targeted therapy and 82 receiving a combination of targeted therapy and Helixor® Viscum album L. therapy. Results
